Mechanistic comparison of Medroxyprogesterone Acetate and Methyltestosterone based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
18
Shared Targets
42%
Jaccard Similarity
35%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.
Medroxyprogesterone and Methyltestosterone share 18 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.419 means 42% of the combined target set is bound by both compounds. The IDF-weighted score of 0.354 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do Medroxyprogesterone and Methyltestosterone have in common?
Medroxyprogesterone and Methyltestosterone share 18 molecular targets with a Jaccard similarity of 42%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can Medroxyprogesterone and Methyltestosterone be combined?
Medroxyprogesterone and Methyltestosterone share 18 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: Medroxyprogesterone or Methyltestosterone?
Both Medroxyprogesterone and Methyltestosterone have substantial PubMed research. View their individual profiles for full evidence scores.